

## Review of Coronary Heart Disease Risk in HIV Treatment Roundtable #1: Approaches to Assessing Coronary Heart Disease (CHD) Risk: Statistical and Epidemiological Issues

Artemis Hotel Amsterdam, The Netherlands May 11, 2010

Keri Althoff, PhD, MPH

Johns Hopkins Bloomberg School of Public Health

Quazi Ataher, MBBS, MHS, PhD

Pfizer

Nisha Chandra-Strobos, MD

Johns Hopkins University School of Medicine

**Dominique Costagliola, PhD** 

**INSERM U943** 

Luuk Graas, MSc

Stichting HIV Monitoring

Giovanni Guaraldi, MD

University of Modena

Miguel Hernán, MD, MPH, ScM, DrPH

Harvard School of Public Health

Sara Hughes, MSc, Cstat

Viiv Healthcare

Filip Josephson, MD, PhD Swedish Medical Products Agency

Karin Klingman, MD

**NIAID-NIH** 

Sylvie Lang, Master

Veronica Miller, PhD

Amy Keller, BS

Arcara Keller LLC

**Kendall Marcus, MD**Food and Drug Administration

Forum for Collaborative HIV Research

**Robert Obenchain, PhD** Risk Benefit Statistics LLC **Maya Petersen, MD, PhD** University of California, Berkeley

**Richard Rode, PhD** Abbott **Caroline Sabin, PhD**University College London

**Neil Shortman, CBiol MSB** ViiV Healthcare

**Jur Strobos, MD, JD**Forum for Collaborative HIV Research

Mark van der Laan, PhD University of California, Berkeley Carolyn Williams, PhD, MPH DAIDS

## Paige Williams, PhD

Harvard School of Public Health

## Stan Young, PhD

National Institute of Statistical Sciences